NO3022387T3 - - Google Patents
Info
- Publication number
- NO3022387T3 NO3022387T3 NO14826414A NO14826414A NO3022387T3 NO 3022387 T3 NO3022387 T3 NO 3022387T3 NO 14826414 A NO14826414 A NO 14826414A NO 14826414 A NO14826414 A NO 14826414A NO 3022387 T3 NO3022387 T3 NO 3022387T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798261P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3022387T3 true NO3022387T3 (sr) | 2018-08-25 |
Family
ID=50928243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14826414A NO3022387T3 (sr) | 2013-03-15 | 2014-07-03 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9556280B2 (sr) |
| EP (1) | EP2970497B1 (sr) |
| JP (4) | JP6454678B2 (sr) |
| CN (2) | CN105452298B (sr) |
| CA (1) | CA2906128A1 (sr) |
| CY (1) | CY1120210T1 (sr) |
| DK (1) | DK2970497T3 (sr) |
| ES (1) | ES2657304T3 (sr) |
| HK (1) | HK1218128A1 (sr) |
| HR (1) | HRP20180078T1 (sr) |
| HU (1) | HUE037907T2 (sr) |
| LT (1) | LT2970497T (sr) |
| NO (1) | NO3022387T3 (sr) |
| PL (1) | PL2970497T3 (sr) |
| PT (1) | PT2970497T (sr) |
| RS (1) | RS56814B1 (sr) |
| SI (1) | SI2970497T1 (sr) |
| WO (1) | WO2014144577A1 (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| CN107108726A (zh) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| EP3262075B1 (en) * | 2015-02-25 | 2024-03-13 | Mogam Institute For Biomedical Research | Novel antibody binding to tfpi and composition comprising the same |
| CN107922506B (zh) | 2015-08-19 | 2021-11-09 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| KR20210074335A (ko) | 2018-10-11 | 2021-06-21 | 화이자 인코포레이티드 | Tfpi 길항제의 투여량 섭생법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588507A (en) * | 2008-04-11 | 2012-11-30 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| JP5714505B2 (ja) | 2008-12-22 | 2015-05-07 | ノヴォ ノルディスク アー／エス | 組織因子経路阻害因子に対する抗体 |
| NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| SG10201507722QA (en) * | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| DK2694544T3 (en) | 2011-04-01 | 2019-04-15 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI) |
| WO2013148248A1 (en) * | 2012-03-30 | 2013-10-03 | Bayer Healthcare Llc | Protease-regulated antibodies |
| CA2881679C (en) * | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| AU2013302966B2 (en) * | 2012-08-15 | 2017-06-08 | Lucid, Inc. | Systems and methods for imaging tissue |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2014
- 2014-03-14 US US14/213,278 patent/US9556280B2/en active Active
- 2014-03-14 CN CN201480016248.5A patent/CN105452298B/zh not_active Expired - Fee Related
- 2014-03-14 LT LTEP14729504.2T patent/LT2970497T/lt unknown
- 2014-03-14 RS RS20180073A patent/RS56814B1/sr unknown
- 2014-03-14 PL PL14729504T patent/PL2970497T3/pl unknown
- 2014-03-14 EP EP14729504.2A patent/EP2970497B1/en active Active
- 2014-03-14 US US14/772,336 patent/US20160009818A1/en not_active Abandoned
- 2014-03-14 PT PT147295042T patent/PT2970497T/pt unknown
- 2014-03-14 CN CN202110987812.XA patent/CN113788897A/zh active Pending
- 2014-03-14 HU HUE14729504A patent/HUE037907T2/hu unknown
- 2014-03-14 CA CA2906128A patent/CA2906128A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029048 patent/WO2014144577A1/en active Application Filing
- 2014-03-14 SI SI201430564T patent/SI2970497T1/en unknown
- 2014-03-14 ES ES14729504.2T patent/ES2657304T3/es active Active
- 2014-03-14 JP JP2016502971A patent/JP6454678B2/ja not_active Expired - Fee Related
- 2014-03-14 DK DK14729504.2T patent/DK2970497T3/da active
- 2014-07-03 NO NO14826414A patent/NO3022387T3/no unknown
-
2016
- 2016-06-02 HK HK16106252.2A patent/HK1218128A1/zh unknown
-
2018
- 2018-01-16 HR HRP20180078TT patent/HRP20180078T1/hr unknown
- 2018-01-24 CY CY20181100096T patent/CY1120210T1/el unknown
- 2018-04-25 US US15/962,624 patent/US20180282430A1/en not_active Abandoned
- 2018-12-17 JP JP2018235059A patent/JP6697064B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-24 JP JP2020009685A patent/JP2020079250A/ja active Pending
-
2021
- 2021-04-16 JP JP2021069872A patent/JP2021107436A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PT2970497T (pt) | 2018-01-30 |
| JP2016514683A (ja) | 2016-05-23 |
| CN105452298A (zh) | 2016-03-30 |
| US20180282430A1 (en) | 2018-10-04 |
| JP2021107436A (ja) | 2021-07-29 |
| US9556280B2 (en) | 2017-01-31 |
| JP2019069973A (ja) | 2019-05-09 |
| JP6454678B2 (ja) | 2019-01-16 |
| RS56814B1 (sr) | 2018-04-30 |
| CN105452298B (zh) | 2021-08-31 |
| JP6697064B2 (ja) | 2020-05-20 |
| LT2970497T (lt) | 2018-03-12 |
| WO2014144577A1 (en) | 2014-09-18 |
| SI2970497T1 (en) | 2018-04-30 |
| HK1218128A1 (zh) | 2017-02-03 |
| ES2657304T3 (es) | 2018-03-02 |
| PL2970497T3 (pl) | 2018-05-30 |
| CY1120210T1 (el) | 2018-12-12 |
| HUE037907T2 (hu) | 2018-09-28 |
| HRP20180078T1 (hr) | 2018-03-09 |
| DK2970497T3 (da) | 2018-01-29 |
| JP2020079250A (ja) | 2020-05-28 |
| CA2906128A1 (en) | 2014-09-18 |
| CN113788897A (zh) | 2021-12-14 |
| US20140275493A1 (en) | 2014-09-18 |
| EP2970497A1 (en) | 2016-01-20 |
| EP2970497B1 (en) | 2017-10-25 |
| US20160009818A1 (en) | 2016-01-14 |